|
BE787901A
(fr)
|
1971-09-11 |
1972-12-18 |
Freistaat Bayern Represente Pa |
Vaccin antivariolique
|
|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
EP1380651A2
(en)
|
1991-08-26 |
2004-01-14 |
Baxter Healthcare S.A. |
Recombinant fowlpox virus with intact FPV-tk-gene
|
|
WO1994012617A1
(en)
|
1992-11-25 |
1994-06-09 |
International Biotechnology Laboratories, Inc. |
Hepatitis b virus vaccines
|
|
EP0942747A1
(en)
|
1996-08-26 |
1999-09-22 |
Chiron Corporation |
Postinfection human immunodeficiency virus (hiv) vaccination therapy
|
|
AUPP380598A0
(en)
|
1998-05-29 |
1998-06-25 |
Commonwealth Scientific And Industrial Research Organisation |
Genetically manipulated entomopoxvirus
|
|
US6294176B1
(en)
|
1998-07-10 |
2001-09-25 |
Schering-Plough Veterinary Corp. |
Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
|
|
CN100446812C
(zh)
|
2001-03-08 |
2008-12-31 |
美国国有健康与人类服务部 |
表达修饰的hiv包膜、gag和pol基因的mva
|
|
US7025970B2
(en)
|
2002-03-15 |
2006-04-11 |
Baxter International Inc. |
Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods
|
|
UA82479C2
(uk)
|
2002-05-16 |
2008-04-25 |
Бавариан Нордика А/С |
Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva)
|
|
US9045727B2
(en)
*
|
2002-05-17 |
2015-06-02 |
Emory University |
Virus-like particles, methods of preparation, and immunogenic compositions
|
|
ATE365220T1
(de)
|
2002-11-25 |
2007-07-15 |
Bavarian Nordic As |
Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
|
|
JP5052893B2
(ja)
|
2003-02-20 |
2012-10-17 |
アメリカ合衆国 |
ポックスベクターにおける新規の挿入部位
|
|
WO2005016238A2
(en)
|
2003-05-08 |
2005-02-24 |
Duke University |
Severe acute respiratory syndrome
|
|
US8080642B2
(en)
*
|
2003-05-16 |
2011-12-20 |
Vical Incorporated |
Severe acute respiratory syndrome DNA compositions and methods of use
|
|
CN1918288A
(zh)
*
|
2003-06-20 |
2007-02-21 |
蛋白质科学公司 |
表达sars免疫原的载体、含所述载体或其表达产物的组合物、制备和使用方法和实验
|
|
EP1668112A4
(en)
|
2003-06-20 |
2009-04-29 |
Protein Sciences Corp |
SARS IMMUNOGENOUS EXPRESSING VECTORS, SUCH VECTORS OR EXPRESSION PRODUCTS COMPRISING THOSE COMPOSITIONS, PROCESSES AND TESTS FOR THE PREPARATION AND USE THEREOF
|
|
WO2005047459A2
(en)
*
|
2003-08-04 |
2005-05-26 |
University Of Massachusetts |
Sars nucleic acids, proteins, antibodies, and uses thereof
|
|
WO2006071250A2
(en)
|
2004-04-05 |
2006-07-06 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Soluble fragments of the sars-cov spike glycoprotein
|
|
WO2005120565A2
(en)
*
|
2004-06-02 |
2005-12-22 |
New York Blood Center |
Sars vaccines and methods to produce highly potent antibodies
|
|
WO2006022215A1
(ja)
*
|
2004-08-23 |
2006-03-02 |
The Japan Health Sciences Foundation |
SARS-コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用
|
|
WO2006026667A2
(en)
|
2004-08-27 |
2006-03-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
|
|
EP2808384B1
(en)
*
|
2004-10-08 |
2017-12-06 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Modulation of replicative fitness by using less frequently used synonymous codons
|
|
CN100479858C
(zh)
*
|
2005-01-27 |
2009-04-22 |
中国医学科学院实验动物研究所 |
一种重组痘苗-sars疫苗及其制备方法
|
|
ES2281252B1
(es)
|
2005-07-27 |
2009-02-16 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
|
|
DK2402451T3
(en)
|
2006-08-25 |
2018-06-25 |
The Government Of The Us Secretary Department Of Health And Human Services |
Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector
|
|
WO2010062757A1
(en)
|
2008-11-03 |
2010-06-03 |
Ligocyte Pharmaceuticals, Inc. |
Improved methods for isolating enveloped virus-based vlps free of infectious agents
|
|
AP2012006258A0
(en)
|
2009-10-13 |
2012-06-30 |
Geovax Inc |
Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.
|
|
WO2011047324A1
(en)
|
2009-10-16 |
2011-04-21 |
The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . |
Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
|
|
AU2011217955A1
(en)
|
2010-02-18 |
2012-08-16 |
Emory University |
Vectors expressing HIV antigens and GM-CSF and related methods for generating an immune response
|
|
TWI526539B
(zh)
*
|
2010-12-22 |
2016-03-21 |
苜蓿股份有限公司 |
植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
|
|
US20130280215A1
(en)
|
2011-10-18 |
2013-10-24 |
Geovax, Inc. |
Mva vectors expressing polypeptides and having high level production in certain cell lines
|
|
EP2869842A1
(en)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Immunogenic compositions and uses thereof
|
|
WO2015009946A1
(en)
|
2013-07-17 |
2015-01-22 |
Emory University |
Method of increasing immune response to hiv antigens
|
|
WO2015066715A1
(en)
|
2013-11-04 |
2015-05-07 |
Viracell Advanced Products, Llc |
Virus-like particles and methods related thereto
|
|
ES2851451T3
(es)
|
2014-05-13 |
2021-09-07 |
Bavarian Nordic As |
Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
|
|
CA2959105C
(en)
|
2014-09-03 |
2023-10-17 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
WO2016068919A1
(en)
|
2014-10-29 |
2016-05-06 |
Geovax, Inc. |
Combination therapy for treating viral reservoirs
|
|
US11701418B2
(en)
|
2015-01-12 |
2023-07-18 |
Geovax, Inc. |
Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
|
|
EP3045181B1
(en)
|
2015-01-19 |
2018-11-14 |
Ludwig-Maximilians-Universität München |
A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
|
|
CN109071592B
(zh)
*
|
2016-01-08 |
2022-07-19 |
吉奥瓦科斯公司 |
用于产生对肿瘤相关抗原的免疫应答的组合物和方法
|
|
EP3402888B1
(en)
*
|
2016-01-12 |
2020-08-26 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Means and methods for treating hbv
|
|
US20190030157A1
(en)
|
2016-02-03 |
2019-01-31 |
Geovax Inc. |
Compositions and Methods for Generating an Immune Response to a Flavivirus
|
|
US11098086B2
(en)
|
2016-02-16 |
2021-08-24 |
Geovax Inc. |
Multivalent HIV vaccine boost compositions and methods of use
|
|
US11052148B2
(en)
*
|
2016-05-30 |
2021-07-06 |
Geo Vax, Inc. |
Compositions and methods for generating an immune response to hepatitis B virus
|
|
WO2018081318A1
(en)
|
2016-10-25 |
2018-05-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion coronavirus spike proteins and their use
|
|
CN115477679A
(zh)
|
2017-02-01 |
2022-12-16 |
阿堤亚制药公司 |
用于治疗丙型肝炎病毒的核苷酸半硫酸盐
|
|
WO2018170347A1
(en)
*
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
WO2018195447A1
(en)
|
2017-04-20 |
2018-10-25 |
Geovax Labs, Inc. |
Recombinant mva-based hiv immunogens and uses thereof
|
|
US20200171141A1
(en)
|
2017-07-18 |
2020-06-04 |
Geovax, Inc. |
Compositions and Methods for Generating an Immune Response to LASV
|
|
US20210220469A1
(en)
|
2017-08-25 |
2021-07-22 |
Geovax, Inc. |
Immuno-Oncology Compositions and Methods for Use Thereof
|
|
US11311612B2
(en)
|
2017-09-19 |
2022-04-26 |
Geovax, Inc. |
Compositions and methods for generating an immune response to treat or prevent malaria
|
|
WO2020247547A1
(en)
|
2019-06-03 |
2020-12-10 |
Geovax, Inc. |
Cancer vaccine compositions and methods for use thereof
|
|
TW202204380A
(zh)
|
2020-01-31 |
2022-02-01 |
美商詹森藥物公司 |
用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
|
|
CN115397998A
(zh)
|
2020-02-03 |
2022-11-25 |
希望之城 |
由天然或合成dna产生的基于痘病毒的载体及其用途
|
|
CN115515627A
(zh)
|
2020-02-11 |
2022-12-23 |
美国政府(由卫生和人类服务部的部长所代表) |
SARS-CoV-2疫苗
|
|
GB2594683A
(en)
|
2020-02-17 |
2021-11-10 |
Vaxbio Ltd |
Vaccine
|
|
BR112022016992A2
(pt)
*
|
2020-02-26 |
2022-10-25 |
Tonix Pharma Ltd |
Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
|
|
KR20220152248A
(ko)
|
2020-03-13 |
2022-11-15 |
옥스포드 유니버시티 이노베이션 리미티드 |
면역 반응을 유도하기 위한 조성물 및 방법
|
|
TW202200199A
(zh)
|
2020-03-20 |
2022-01-01 |
美商百歐恩泰美國公司 |
冠狀病毒疫苗及使用方法
|
|
US20240210415A1
(en)
|
2020-03-24 |
2024-06-27 |
Icahn School Of Medicine At Mount Sinai |
Recombinant sars-cov-2 spike protein and uses thereof
|
|
TW202203966A
(zh)
|
2020-03-31 |
2022-02-01 |
澳大利亞商賽門蒂斯公司 |
用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗
|
|
WO2021198706A2
(en)
|
2020-04-01 |
2021-10-07 |
Diosynvax Ltd |
Coronavirus vaccines
|
|
WO2021216743A2
(en)
|
2020-04-21 |
2021-10-28 |
Emory University |
Coronavirus vaccines, compositions, and methods related thereto
|
|
EP4153228A4
(en)
|
2020-05-17 |
2024-07-10 |
City of Hope |
CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
|
|
US11130787B2
(en)
*
|
2020-06-11 |
2021-09-28 |
MBF Therapeutics, Inc. |
Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods
|
|
EP3928789A1
(en)
*
|
2020-06-24 |
2021-12-29 |
Consejo Superior de Investigaciones Científicas (CSIC) |
Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
|
|
BR112023015467A2
(pt)
|
2021-02-02 |
2023-10-10 |
Geovax Inc |
Vetor viral de vaccinia ankara recombinante modificado, métodos para aumentar uma resposta imunológica a um antígeno alvo em um paciente e para prevenir, tratar ou induzir uma resposta imunológica contra um antígeno alvo, e, composição farmacêutica
|